Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial

What Was Tested

This randomized controlled trial paper looks at Teriparatide.

Pelvic fracture patients were randomized to blinded daily subcutaneous teriparatide (TPTD) or placebo to assess healing and functional outcomes over 3 months.

Who Took Part

The study group was 35 patients.

By PubMed's age tags, the people studied were middle-aged adults and people over 80, both men and women.

This randomized, placebo-controlled study enrolled 35 patients (women and men >50 years old) within 4 weeks of pelvic fracture and evaluated the effect of blinded TPTD vs placebo over 3 months on fracture healing.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Teriparatide and who got the comparison, which limits bias.

Some patients received a placebo instead of Teriparatide, giving a reference point.

Fracture healing from CT images at 0 and 3 months was assessed as cortical bridging using a 5-point scale.

The numeric rating scale (NRS) for pain was administered monthly.

Physical performance was assessed monthly by Continuous Summary Physical Performance Score (based on 4 m walk speed, timed repeated chair stands, and balance) and the Timed Up and Go (TUG) test.

What Was Measured

The subject headings attached to it are Bone Density Conservation Agents, Fracture Healing, Fractures, Bone, Spinal Fractures and Teriparatide.

The authors tagged it with the keywords Pain, Pelvic fracture, Physical performance and Placebo.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Teriparatide in 35 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Teriparatide compound page.